JHEP Reports

Papers
(The H4-Index of JHEP Reports is 40. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Copyright and information164
Protective role of physical activity against HCC risk in type 2 diabetes: Evidence and public health perspectives115
Reply to: “Dynamic imaging of macrophages in MASLD: A major interest in insulin resistance and outside the liver”105
Inevitability of disease recurrence after liver transplantation for NAFLD cirrhosis90
Erratum to “Opinion paper on the diagnosis and treatment of progressive familial intrahepatic cholestasis” [JHEP Reports 6 (2024) 100949]88
The weight of choices: Prioritizing lifestyle over GLP-1 receptor agonist therapy in managing MASLD86
Time for a globally unified chronic HBV terminology?80
Changing epidemiology of hepatocellular carcinoma in the Mediterranean area: A challenge for surveillance?79
Hepatitis C virus replication requires integrity of mitochondria-associated ER membranes78
Statistical precision of p values: A note on “Liver fibrosis progression analyzed with AI predicts renal decline”75
Editorial Board page74
A small animal model of chronic hepatitis E infection using immunocompromised rats68
JMJD2D stabilises and cooperates with HBx protein to promote HBV transcription and replication65
Development and validation of circulating protein signatures as diagnostic biomarkers for biliary tract cancer62
Combined inhibition of bile salt synthesis and intestinal uptake reduces cholestatic liver damage and colonic bile salts in mice60
Mapping the hemodynamic effects of terlipressin in patients with hepatorenal syndrome using advanced magnetic resonance imaging59
Liver stiffness measurement predicts clinical outcomes in autoimmune hepatitis58
MELD 3.i: A Bayesian framework for updating the model for end-stage liver disease score58
Long-term antigen reduction does not achieve durable HBV control in mice but enhances therapeutic vaccine efficacy57
Heterogeneity in intrahepatic macrophage populations and druggable target expression in patients with steatotic liver disease-related fibrosis57
Predicting liver ablation volumes with real-time MRI thermometry56
AFP score and metroticket 2.0 perform similarly and could be used in a “within-ALL” clinical decision tool55
Increasing incidence and changing trends in etiology & survival rates in HCC in a European cohort52
External validation of the IAIHG autoimmune hepatitis response criteria in a multicentric real-world cohort52
Clinical features and management for CDK4/6 inhibitor-DILI51
What to do about hepatocellular carcinoma: Recommendations for health authorities from the International Liver Cancer Association51
HCV microelimination in harm reduction centres has benefits beyond HCV cure but is hampered by high reinfection rates51
Contents50
Intrahepatic T cell analysis reveals Th17 and MAIT17 enrichment in primary sclerosing cholangitis49
Unaddressed concerns of potential follow-up bias in the international PSC registry49
Integrative Multi-Omics Analysis Identifies Stellate Cell-Derived Complement Component 7 as a Predictor of Fibrosis and Liver-Related Events in MASLD Patients48
Shunt magnitude is a key determinant of overt hepatic encephalopathy in patients undergoing TIPS48
Comparative effectiveness of antidiabetic therapies on hepatic decompensation in patients with type 2 diabetes: A target trial emulation45
Induction of phospholipase A2 group 4C by HCV infection regulates lipid droplet formation45
Lower pretreatment HBV DNA levels are associated with better off-treatment outcomes after nucleo(s)tide analogue withdrawal in patients with HBeAg-negative chronic hepatitis B: A multicentre cohort st45
Identifying emergency presentations of chronic liver disease using routinely collected administrative hospital data45
Editorial Board page41
Progression to cirrhosis in chronic hepatitis D with mild-to-moderate fibrosis: Insights from a multicenter European cohort41
Human umbilical cord mesenchymal stem cell-derived exosomes ameliorate liver steatosis by promoting fatty acid oxidation and reducing fatty acid synthesis41
Reply to: “Changing epidemiology of hepatocellular carcinoma in the Mediterranean area: A challenge for surveillance?”40
0.64623284339905